

## AMENDMENT TO THE CLAIMS

Claims 1-53 (canceled)

54 (new) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence of SEQ ID NO:2, or a complement thereof.

55 (new) The nucleic acid molecule of claim 54, wherein the nucleic acid molecule comprises a nucleic acid sequence having at least 80% nucleic acid sequence identity to the nucleic acid of SEQ ID NO:1.

56 (new) The nucleic acid molecule of claim 54, wherein the nucleic acid molecule comprises a nucleic acid sequence having at least 85% nucleic acid sequence identity to the nucleic acid of SEQ ID NO:1.

57 (new) The nucleic acid molecule of claim 54, wherein the nucleic acid molecule comprises a nucleic acid sequence having at least 90% nucleic acid sequence identity to the nucleic acid of SEQ ID NO:1.

58 (new) The nucleic acid molecule of claim 54, wherein the nucleic acid molecule comprises a nucleic acid sequence having at least 95% nucleic acid sequence identity to the nucleic acid of SEQ ID NO:1.

59 (new) The nucleic acid molecule of claim 54, wherein the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO:1.

60 (new) A vector comprising the nucleic acid molecule of claim 54.

61 (new) The vector of claim 60, further comprising a promoter operably-linked to the nucleic acid molecule.

62 (new) A cell comprising the vector of claim 60.

63 (new) A pharmaceutical composition comprising the nucleic acid molecule of claim 54 and a pharmaceutically-acceptable carrier.

64 (new) A kit comprising in one or more containers, the pharmaceutical composition of claim 63.